PubRank

Elaine Coustan-Smith

Author PubWeight™ 79.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007 17.68
2 The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012 9.89
3 Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 7.95
4 Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009 4.35
5 Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010 3.76
6 Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009 2.97
7 Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012 2.55
8 A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007 2.19
9 Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012 2.14
10 High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011 1.68
11 Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K. J Exp Med 2012 1.66
12 Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011 1.52
13 Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010 1.47
14 Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006 1.41
15 Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005 1.35
16 Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 2003 1.33
17 Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014 1.31
18 Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012 1.30
19 Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012 1.27
20 Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2010 1.16
21 Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol 2011 1.10
22 Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 2009 1.07
23 Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013 0.98
24 Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica 2006 0.98
25 Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer 2008 0.95
26 Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002 0.94
27 Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004 0.91
28 Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol 2014 0.84
29 Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2014 0.84
30 Measurements of treatment response in childhood acute leukemia. Korean J Hematol 2012 0.84
31 Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19. Blood 2011 0.83
32 Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells. Haematologica 2002 0.80
33 Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 2003 0.80
34 WT1 protein expression in childhood acute leukemia. Am J Hematol 2008 0.79
35 Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia. Pediatr Blood Cancer 2013 0.75